首页> 外文期刊>Phytotherapy research: PTR >A randomized, double blind, placebo - Controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder
【24h】

A randomized, double blind, placebo - Controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder

机译:一项随机,双盲,安慰剂对照的前瞻性临床研究,旨在证明固定的缬草蛇麻草提取物组合(Ze 91019)在非有机睡眠障碍患者中的​​临床疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Valerian and hops are traditionally used as sleep aids. Since the fixed extract combination (Ze 91019) as a whole is considered the active compound, the clinical efficacy must be demonstrated for this extract combination. The present clinical study aimed to demonstrate superiority of the fixed extract combination in comparison with placebo in patients suffering from non-organic insomnia (ICD 10, F 51.0-51.2). Objective sleep parameters were registered by means of a transportable home recorder system (QUISI). The primary outcome was the reduction in sleep latency (SL2) which had to be prolonged at baseline (>= 30 min) as an inclusion criteria. The treatment period lasted for 4 weeks with either placebo, single valerian extract (Ze 911) or the fixed valerian hops extract combination (Ze 91019). The amount of the single valerian extract was identical to that amount contained in the fixed extract combination, i.e. 500 mg valerian extract siccum. In the extract combination 120 mg hops extract siccum was added. Both the extracts were prepared with 45% methanol m/ m with a drug-extract ratio of 5.3:1 (valerian) and 6.6:1 (hops), respectively. The fixed extract combination was significantly superior to the placebo in reducing the sleep latency whilst the single valerian extract failed to be superior to the placebo. The result underlined the plausibility for adding hops extract to the valerian extract. Copyright (C) 2007 John Wiley & Sons, Ltd.
机译:缬草和啤酒花传统上用作助眠剂。由于整体上将固定的提取物组合(Ze 91019)视为活性化合物,因此必须证明该提取物组合的临床疗效。本临床研究旨在证明固定提取物组合与安慰剂相比在非有机失眠患者中具有优越性(ICD 10,F 51.0-51.2)。通过便携式家庭记录器系统(QUISI)记录客观睡眠参数。主要结果是减少睡眠潜伏期(SL2),这必须在基线(> = 30分钟)处延长作为纳入标准。用安慰剂,单一缬草提取物(Ze 911)或固定缬草蛇麻草提取物组合(Ze 91019)治疗期为4周。单个缬草提取物的量与固定提取物组合中所含的量相同,即500 mg缬草提取物干燥。在提取物组合中,加入120mg啤酒花提取物干燥的稻草。两种提取物均用45%甲醇m / m制备,药物提取比分别为5.3:1(缬草)和6.6:1(蛇麻草)。固定的提取物组合在减少睡眠潜伏期方面显着优于安慰剂,而单一的缬草提取物未能优于安慰剂。结果强调了将啤酒花提取物添加到缬草提取物中的合理性。版权所有(C)2007 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号